AVTXHealthcare · BiotechnologyAVTX Stock Forecast: Avalo Therapeutics, Inc. Price Predictions for 2026-2027
The 15 Wall Street analysts covering Avalo Therapeutics, Inc. hold a median 12-month price target of $42 — +132.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 66 of 100 as at 1 Aug 2026 — in the upper half.
AVTX stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Avalo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Volatility (27): The share price moves around a lot.
The rank is the raw material. Whether the rules would actually own Avalo Therapeutics, Inc. — and when they’d sell — is the membership.
AVTX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on AVTX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +132.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 July 2026 | Leerink Partners | Initiates | Outperform | $38 |
| 16 June 2026 | BTIG | Reiterates | Buy | — |
| 12 June 2026 | B of A Securities | Initiates | Buy | — |
| 14 May 2026 | Citizens | Maintains | Market Outperform | — |
| 14 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 May 2026 | Mizuho | Maintains | Outperform | — |
| 14 May 2026 | Wedbush | Maintains | Outperform | — |
| 11 May 2026 | Piper Sandler | Maintains | Overweight | — |
| 6 May 2026 | BTIG | Maintains | Buy | — |
| 6 May 2026 | Citizens | Maintains | Market Outperform | — |
| 6 May 2026 | Wedbush | Maintains | Outperform | — |
| 13 Apr 2026 | BTIG | Reiterates | Buy | — |
| 9 Apr 2026 | Wolfe Research | Initiates | Outperform | — |
| 6 Apr 2026 | Citizens | Initiates | Market Outperform | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Mar 2026 | BTIG | Reiterates | Buy | — |
| 2 Feb 2026 | Guggenheim | Initiates | Buy | — |
| 15 Jan 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2025 | Mizuho | Initiates | Outperform | — |
| 29 Sept 2025 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
AVTX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Avalo Therapeutics, Inc. (AVTX) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 2.3×
- Price / sales
- 16364.1×
- Price / book
- 6.6×
- EV / EBITDA
- −11.1×
Cheaper than 69% of US stocks
Cheaper than 1% of US stocks
Cheaper than 16% of US stocks
Cheaper than 85% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −134164.4%
- Net margin
- 100.0%
Higher than 1% of US stocks
Higher than 1% of US stocks
Higher than 99% of US stocks
- Return on equity
- −88.8%
- Return on assets
- −41.5%
- Dividend yield
- —
Higher than 14% of US stocks
Higher than 10% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
AVTX vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVTX appears on the weeks it earns a place.
Frequently asked questions about AVTX stock
What is the AVTX stock price forecast for 2026-2027?
The 15 Wall Street analysts covering Avalo Therapeutics, Inc. have a median 12-month price target of $42, with estimates ranging from $34 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is AVTX stock a buy right now?
Of the 15 analysts covering Avalo Therapeutics, Inc., 15 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalo Therapeutics, Inc. 66 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank AVTX?
As at 1 Aug 2026, Avalo Therapeutics, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
Will AVTX stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts implies +132.7% from the last close, and Ticker Nerd's factor model ranks Avalo Therapeutics, Inc. 66 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the AVTX stock forecast for 2030?
No analyst covering Avalo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $60 over the next 12 months.
How has AVTX stock performed over the past year?
Avalo Therapeutics, Inc. returned +128.8% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Avalo Therapeutics, Inc. do?
Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases with significant unmet needs.
About Avalo Therapeutics, Inc.
Avalo Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases with significant unmet needs. The company targets the IL-1β pathway, a central driver of inflammation, through its lead asset, abdakibart (AVTX-009), a humanized monoclonal antibody currently in a Phase 2 LOTUS trial for hidradenitis suppurativa, a chronic inflammatory skin condition. Avalo Therapeutics Inc. is exploring the potential of AVTX-009 in additional immune-mediated indications to address broader patient populations. Founded in 2011 and headquartered in Wayne, Pennsylvania, the company focuses on advancing novel therapeutics driven by scientific innovation and compassion for those affected by chronic inflammatory conditions. Its pipeline emphasizes best-in-class medicines to transform lives in areas lacking effective therapies, operating within the health technology sector to develop and potentially commercialize targeted biologics for immune dysregulation.
CEO Dr. Garry A. Neil M.D. · 23 employees · United States · https://www.avalotx.com